Page 17 - கூட்டணி க்கு பெருவாரியாக பரவும் தொற்று நோய் ப்ரிப்யாரெட்நெஸ் கண்டுபிடிப்பு News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Vials with a sticker reading, COVID-19 / Coronavirus vaccine / Injection only and a medical syringe are seen in front of a displayed Novavax logo in this illustration taken October 31, 2020. REUTERS/Dado Ruvic/Illustration/File Photo
Novavax Inc said on Thursday its coronavirus vaccine was 89.3% effective in preventing COVID-19 in a trial conducted in the United Kingdom, and was nearly as effective in protecting against the more highly contagious variant first discovered in the UK, according to a preliminary analysis.
A mid-stage trial of the vaccine in South Africa, where a troubling new variant of the virus is common, showed 60% effectiveness among people who did not have HIV.
Novavax Inc. said Thursday its coronavirus vaccine was 89.3% effective in preventing COVID-19 in a trial conducted in the United Kingdom, and was nearly as effective in protecting against the more highly contagious variant first discovered in the U.K., according to a preliminary analysis.
A mid-stage trial of the vaccine in South Africa, where a new variant of the virus is common, showed 60 per cent effectiveness among people who did not have HIV.
Novavax is already stockpiling vaccine at six operating manufacturing locations, and said it expects a total of eight plants in seven countries to produce at the rate of 2 billion doses per year, including from the Serum Institute of India.